Selective &bgr;3 adrenergic agonists
    9.
    发明授权
    Selective &bgr;3 adrenergic agonists 失效
    选择性β3肾上腺素激动剂

    公开(公告)号:US06617347B1

    公开(公告)日:2003-09-09

    申请号:US09443272

    申请日:1999-11-18

    IPC分类号: A61K31415

    摘要: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: or pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明在医药领域,特别是治疗II型糖尿病和肥胖症。 更具体地,本发明涉及可用于治疗II型糖尿病和肥胖症的选择性β3受体激动剂。 本发明提供了治疗II型糖尿病和肥胖症的化合物和方法,包括向有需要的哺乳动物施用式I化合物或其药学上可接受的盐。

    Selective &bgr;3 adrenergic agonists
    10.
    发明授权
    Selective &bgr;3 adrenergic agonists 失效
    选择性β3肾上腺素激动剂

    公开(公告)号:US06232337B1

    公开(公告)日:2001-05-15

    申请号:US09554422

    申请日:2000-05-12

    IPC分类号: A61K31415

    CPC分类号: C07D231/18 A61K31/415

    摘要: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I) or a pharmaceutically acceptable salt thereof. The variables of formula (I) have the meanings defined herein.

    摘要翻译: 本发明在医药领域,特别是治疗II型糖尿病和肥胖症。 更具体地,本发明涉及可用于治疗II型糖尿病和肥胖症的选择性β3受体激动剂。 本发明提供了治疗II型糖尿病和肥胖症的化合物和方法,包括向有需要的哺乳动物施用式(I)化合物或其药学上可接受的盐。 式(I)的变量具有本文定义的含义。